Innate Pharma Gestion

Gestion contrôle des critères 4/4

Le PDG Innate Pharma est Herve Brailly, nommé en Jan1999, a un mandat de 25.75 ans. détient directement 0.91% des actions de la société, d'une valeur de € 1.28M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.6 ans et 5.9 ans.

Informations clés

Herve Brailly

Directeur général

€100.0k

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	25.8yrs
Propriété du PDG	0.9%
Durée moyenne d'occupation des postes de direction	4.6yrs
Durée moyenne du mandat des membres du conseil d'administration	5.9yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Herve Brailly (63 yo)

25.8yrs

Titularisation

€100,000

Compensation

Dr. Herve Brailly, Ph.D. Co-Founded Innate Pharma S.A in 1999 and served as its Chairman of Supervisory Board since December 31, 2016 until January 1, 2024 and serves as its Interim CEO and Chairman of the...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Herve Brailly	Co-Founder	25.8yrs	€100.00k	0.91% € 1.3m
Yannis Morel	Executive VP	9.4yrs	€599.92k	0.24% € 334.8k
François Romagné	Founder	no data	pas de données	pas de données
Eric Vivier	Founder	6.8yrs	pas de données	0.26% € 362.4k
Marc Bonneville	Founder	no data	pas de données	pas de données
Jean Fournié	Founder	no data	pas de données	pas de données
Alessandro Moretta	Founder	no data	pas de données	pas de données
Frederic Lombard	Senior VP & CFO	3.5yrs	pas de données	0.014% € 19.6k
Sonia Quaratino	Executive VP	less than a year	pas de données	pas de données
Arvind Sood	Executive VP	less than a year	pas de données	pas de données
Henry Wheeler	Vice President of Investor Relations & Communication	1.8yrs	pas de données	0.0039% € 5.5k
Odile Belzunce	Vice President of Compliance & Operations	5.8yrs	pas de données	0.077% € 107.3k

4.6yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IDDA est considérée comme expérimentée (ancienneté moyenne 4.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Mario Sznol	Strategic Advisory Board Member	5.9yrs	pas de données	pas de données
Olivier Martinez	Member of Supervisory Board	no data	pas de données	pas de données
Diane Mathis	Strategic Advisory Board	less than a year	pas de données	pas de données
Gilles Brisson	Independent Member of Supervisory Board	17.3yrs	€29.00k	0.090% € 126.0k
Sally Bennett	Independent Supervisory Board Member	2.4yrs	€45.00k	0.0031% € 4.3k
Jean-Yves Blay	Independent Member of Supervisory Board	6.8yrs	€29.00k	0.000060% € 83.7
Irina Staatz-Granzer	Independent Chairwoman of Supervisory Board	15.3yrs	€42.00k	0.031% € 43.3k
Pascale Boissel	Independent Vice Chairperson of the Supervisory Board	4.4yrs	€60.00k	0.0012% € 1.7k
Miriam Merad	Chairman of Strategic Advisory Board	5.9yrs	pas de données	pas de données
Veronique Chabernaud	Independent Member of Supervisory Board	9.5yrs	€48.00k	0.00082% € 1.1k
Katy Rezvani	Strategic Advisory Board	less than a year	pas de données	pas de données
Aurelien Marabelle	Strategic Advisory Board Member	5.9yrs	pas de données	pas de données

5.9yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IDDA sont considérés comme expérimentés (ancienneté moyenne 5.9 ans).

Innate Pharma Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Innate Pharma SA Announces Board Changes

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Supervisory Board Changes

Recent updates

Innate Pharma SA Announces Board Changes

Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology

Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022

Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023

Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides

Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

Innate Pharma S.A. Announces Supervisory Board Changes

Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial

Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen